Cholangiocarcinoma News

Amplity Health Designated “Trusted Partner” of Cholangiocarcinoma Foundation

Web Exclusives — February 3, 2021

February 1, 2021 (Cranbury, NJ): The Cholangiocarcinoma Foundation (CCF) designated Amplity Health as a “Trusted Partner,” 1 of only 4 organizations globally. A CCF “Trusted Partner” shares the CCF mission: to find a cure and improve the quality of life for those affected by cholangiocarcinoma (CCA). These 4 esteemed partners are fundamental to the Foundation’s growth and ability to provide high-quality programs and services to the CCA community.

Amplity Health’s designation is based on one of CCF’s core values: the patient is first in everything we do. As a global strategic medical communications and education company, Amplity Health strives to develop and deliver contemporary educational information for all stakeholders in the healthcare ecosystem. Working together with CCF on the Cholangiocarcinoma Summit, CCA News, and Conquering Cholangiocarcinoma has allowed both organizations to achieve their shared goal of improving the lives of CCA patients and caregivers. This specific partnership has significantly increased the impact of educational outreach and built relationships with key stakeholders within the CCA ecosystem. This is important because the speed at which the science of CCA is moving, immediate and broad dissemination of information is crucial to the care of the patient.

“Partnerships are at the heart of the way we work. The relationships we build with our partners allow us to leverage resources, extend our reach in all aspects, and widen our work’s impact. It is important for us to know that our partners have shared values, among other important factors. We are very grateful for the excellent work our partners have helped accomplish for this community,” said Stacie Lindsey, CCF Founder and CEO.

“It is a sincere honor to be recognized as a trusted partner of the Cholangiocarcinoma Foundation,” said Nick Englezos, Publisher of CCA News and CONQUER magazine. “CCF’s contribution to CCA News and CONQUER: the patient voice has added tremendous value for healthcare providers, patients, caregivers, and family members of those with cholangiocarcinoma. As a Steering Committee member of the CCA Summit, CCF has been instrumental in identifying faculty and topics for the Summit, which has elevated our ability to impact the CCA community.”

About Cholangiocarcinoma

Cholangiocarcinoma, a highly lethal rare cancer with poor prognosis, arises from the bile ducts in the liver. With approximately 10,000 cases a year being diagnosed in the United States, cholangiocarcinoma is the second most common primary liver cancer in the world. It is often diagnosed at advanced stages when treatment is only minimally effective, emphasizing the imminent need for novel therapies.

About Amplity Health
The true partner of global healthcare companies, Amplity Health delivers tailored medical and commercial solutions that scale throughout the life cycle of your drug. Amplity is a global authority in scientific stakeholder engagement, go-to-market strategies, and is built upon our belief in the power of face-to-face interaction that nurtures trust with physicians, patients, and payers, allowing for the exchange of complex ideas. We are proud of our inclusive culture and our EPIIC values. Amplity has the expertise, global infrastructure, and data-driven insights to help clients overcome their medical and commercial challenges. Amplity’s wide-ranging capabilities include clinical and medical outsourced teams; clinical and medical capability development; companion diagnostic and precision medicine solutions; medical communications; expert engagement; remote and field solutions for patients, payers, and physicians; and strategic and access consulting. Amplity’s one-of-a-kind Insights database offers clients a detailed view into patient–provider interactions and provider treatment rationale not found through any other provider. For more information, visit amplity.com. Connect with Amplity on Twitter and LinkedIn. Amplity Health is a portfolio company of Altamont Capital Partners.

About Altamont Capital Partners
Altamont Capital Partners is a private investment firm based in the San Francisco Bay Area with more than $3.5 billion of assets under management. Altamont is focused on investing in middle market businesses where it can partner with leading management teams to help its portfolio companies reach their full potential. The firm’s principals have significant experience building business success stories across a range of industries, including healthcare, business services, financial services, consumer/retail, and industrials.

About CCA News

CCA News is an important new publication highlighting the latest research and development in cholangiocarcinoma (CCA). It is a focused publication on biliary tract cancers. This journal reviews the latest clinical research in CCA and biliary tract cancers based on the peer-reviewed literature, oncology meetings, and updates on developments in new drugs.

Subscribe to CCA News

About the CCA Summit

The CCA Summit focuses on the epidemiology, pathology, translational/basic science, and clinical research impacting the management of patients with CCA. Viewpoints will be heard from medical and surgical oncologists, interventional radiologists, gastroenterologists, and pathologists regarding unmet needs in the treatment of patients with CCA, and the latest approaches to medical and surgical treatment options will be examined. In addition to a deep dive into CCA, gallbladder and biliary cancers will also be assessed.

Learn more about the Cholangiocarcinoma Summit

About the Cholangiocarcinoma Foundation

Founded in 2006, the Cholangiocarcinoma Foundation (CCF) is a global 501(c)(3) nonprofit organization whose mission is to find a cure and improve the quality of life for those affected by bile duct cancer. CCF supports basic and translational research and raises awareness in the cholangiocarcinoma community through advocacy, education, collaboration, and research.

Learn more about the Cholangiocarcinoma Foundation

CONQUER: the patient voice™

CONQUER magazine is the Academy of Oncology Nurse & Patient Navigators (AONN+) premier forum for patients with cancer. CONQUER features articles written by and for patients with cancer, survivors, nurse navigators, and other oncology team members. This magazine addresses the issues that patients, their family members, and caregivers face every day in an easy-to-read format. Issues include interviews with patients with cancer, information on access to care, and articles on lifestyle topics such as nutrition, stress management, personal finance, and legal and employer issues. CONQUER also features patient stories that are nominated for the AONN+ Hero of Hope™ award, which is presented at the AONN+ Annual Conference. All stories are compiled in a special issue of CONQUER at the end of the year.

Learn more about CONQUER

Related Items

October 10, 2022: IMPORTANT INFORMATION ABOUT TRUSELTIQ
Web Exclusives
Helsinn Therapeutics, Inc. has released an important announcement about the discontinuation of distribution of TRUSELTIQ® (infigratinib) capsules as of the first quarter of 2023. It is important to note that this discontinuation is not for safety or efficacy reasons but is based on difficulties in recruiting and enrolling study subjects for the required confirmatory clinical trial.
An Open End-of-Year Appreciation Letter
Web Exclusives
As the end of this year draws near, we at Amplity Health would like to take this opportunity to thank all of you for an amazing 2020. We also share a celebration of our victories and accomplishments with everyone, while reflecting on ways to improve as we progress into the new year! The success of Amplity Medical Communications is based on the effective and vibrant relationships we have forged over the years; we simply wouldn’t be where we are without you. We are extremely grateful for the opportunity to work with, and for you!

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: